MedPath

Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis (SELECT)

Phase 3
Completed
Conditions
Deep Vein Thrombosis
Interventions
Procedure: D-dimer testing
Registration Number
NCT00157677
Lead Sponsor
McMaster University
Brief Summary

The purpose of this study is to compare two diagnostic interventions to improve the way D-dimer blood testing (MDA D-dimer) is used to diagnose first time symptomatic deep vein thrombosis.

Detailed Description

* Limiting use of D-dimer testing to outpatients with a Low or Moderate clinical pretest probability (C-PTP)for deep vein thrombosis AND using a D-dimer level of \< 1.0 µg FEU/mL to exclude deep vein thrombosis in those with a Low C-PTP, and a D-dimer level of \< 0.5 µg FEU/mL to exclude deep vein thrombosis in those with a Moderate C-PTP, is as safe and a more efficient way to diagnose DVT than:

* Performing D-dimer testing in all patients with suspected deep vein thrombosis with use of a single D-dimer value of \< 0.5 µg FEU/mL to exclude thrombosis (current practice).

All randomized patients, including those who are treated for deep vein thrombosis after initial testing, will be followed for a period of 3 months to monitor for signs and symptoms suggestive of deep vein thrombosis, pulmonary embolism, bleeds and death.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1727
Inclusion Criteria
  • Age 18 and older
  • Presenting with symptoms compatible with clinically suspected deep vein thrombosis
Exclusion Criteria
  • Treatment with full dose anticoagulation for 24 hours or more.
  • Other test for deep vein thrombosis already performed.
  • Ongoing need for therapeutic anticoagulant therapy.
  • Life expectancy less than 3 months.
  • Absence of acute symptoms within 7 days of presentation.
  • Presenting with symptoms of pulmonary embolism.
  • Previous confirmed episode of deep vein thrombosis or pulmonary embolism.
  • Current pregnancy.
  • Geographic inaccessibility which precludes follow-up.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2D-dimer testingUniform D-Dimer use
1D-dimer testingSelective D-Dimer use
Primary Outcome Measures
NameTimeMethod
objectively confirmed proximal deep vein thrombosis or pulmonary embolism during 3 months of follow-up in patients who are not diagnosed with deep vein thrombosis during diagnostic testing and are not anticoagulated3 Months
Secondary Outcome Measures
NameTimeMethod
bleeding3 Months
healthcare utilization3 Months
cost-effectiveness3 Months

Trial Locations

Locations (5)

Hamilton Health Sciences, McMaster

🇨🇦

Hamilton, Ontario, Canada

St. Joseph's Health Care Centre

🇨🇦

Hamilton, Ontario, Canada

SMBD Jewish General Hospital

🇨🇦

Montreal, Quebec, Canada

Hamilton Health Sciences, General

🇨🇦

Hamilton, Ontario, Canada

Hamilton Health Sciences, Henderson

🇨🇦

Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath